Macular degeneration does not cause total blindness. It destroys central vision, the sharp, detailed sight you use to read, recognize faces, and drive, but it leaves peripheral (side) vision intact. That said, severe cases can result in legal blindness, which is a specific threshold defined as 20/200 vision or worse in your better eye. AMD is the most common cause of legal blindness in people over 60.
Central Vision vs. Total Vision Loss
The macula is a small area at the center of your retina packed with cone cells, the photoreceptors responsible for sharp, detailed, color vision. When these cells die, you lose the ability to see what’s directly in front of you. Imagine looking at someone’s face and seeing everything around them clearly, but their face itself is blurred or blacked out. That missing or distorted center is called a scotoma.
The rest of your retina, which handles peripheral vision, stays healthy. This means you can still see to the sides, navigate a room, and avoid bumping into things. You won’t go dark. Johns Hopkins Medicine specifically notes that patients “can rest assured that their peripheral vision, and their ability to walk around without bumping into things, is usually preserved.” The fear of waking up in complete darkness is understandable, but that’s not how this disease works.
What Legal Blindness Actually Means
Legal blindness is not the same as seeing nothing. The Social Security Administration defines it as central visual acuity of 20/200 or less in your better eye with corrective lenses, or a visual field narrowed to 20 degrees or less. At 20/200, what a person with normal vision can read from 200 feet away, you’d need to be 20 feet away to read. About 14 million people worldwide are blind or severely visually impaired because of AMD, and the disease accounts for roughly 8.7% of all global blindness.
Among people with the advanced dry form (geographic atrophy) who were not legally blind at diagnosis, about 16% progressed to legal blindness over the following years, with a median time to that progression of 6.2 years.
How the Two Forms Progress Differently
AMD comes in two forms, and they threaten your vision on very different timelines.
Dry AMD is far more common, accounting for about 85% of cases. Vision loss is gradual. Most people with dry AMD never completely lose central vision. However, the advanced stage, called geographic atrophy, involves expanding patches of dead retinal tissue that can eventually reach the fovea, the very center of the macula. Once that happens, central vision drops sharply. The median time for atrophic lesions to reach the fovea is 1.4 to 2.5 years once they’ve formed, and from there, visual acuity declines quickly.
Wet AMD is less common (about 15% of AMD patients) but more aggressive. It occurs when abnormal, leaky blood vessels grow beneath the macula. These vessels can cause sudden, acute vision loss. Without treatment, wet AMD can lead to rapid and total loss of central vision. It’s responsible for the majority of severe vision loss from the disease, though roughly 20% of AMD-related legal blindness comes from the dry form.
How Treatment Changes the Outlook
For wet AMD, regular eye injections that block the growth signal driving those abnormal blood vessels have transformed outcomes over the past two decades. In a real-world study tracking patients over 10 years of treatment, 63.3% of treated eyes lost fewer than 15 letters on a standard eye chart, which is the threshold for significant vision loss. Vision still declined on average (about 11 letters over a decade), but the disease was kept in check well enough that most patients maintained functional sight. Before these injections existed, wet AMD almost always meant rapid, severe central vision loss.
For dry AMD, a specific combination of antioxidant vitamins and minerals (known as the AREDS2 formula, widely available over the counter) reduces the risk of progressing from intermediate to advanced AMD by about 25 to 30%. This doesn’t reverse damage already done, but it can meaningfully slow the march toward severe vision loss. Newer treatments targeting the advanced dry form are also now available.
What Daily Life Looks Like
The practical impact of AMD centers on tasks that require fine detail and central focus. Reading becomes difficult or impossible without magnification aids. Recognizing faces gets harder. Driving is often the first major activity people lose: a UK study found that two-thirds of patients with geographic atrophy in both eyes who could still drive at baseline lost enough vision to become ineligible, with a median time to that point of just 1.6 years.
Simulator studies also show that people with central vision loss have delayed responses to stop signs and traffic lights, which makes sense when the scotoma sits right where you’d normally look. Cooking, reading medication labels, and seeing screens all become challenging in similar ways.
That said, many people with AMD adapt with the help of low-vision aids: magnifiers, large-print devices, text-to-speech software, and improved lighting. Peripheral vision carries a lot of independence. People with AMD continue to live at home, move freely, and maintain social lives, even when central vision is significantly impaired.
Catching Changes Early
One of the simplest monitoring tools is the Amsler grid, a square pattern of evenly spaced horizontal and vertical lines. You hold it at reading distance (about 45 cm), cover one eye, and look at the center dot. If any of the straight lines appear wavy, blurred, or missing, that’s a sign of macular changes. It covers the central 12.5 degrees of your visual field, right where AMD does its damage. Eye doctors typically recommend checking it daily, since catching a shift from dry to wet AMD early can mean the difference between saving and losing central vision.
Regular dilated eye exams remain the most reliable way to track progression. Imaging technology now allows doctors to detect structural changes in the retina before you notice any symptoms, which opens a window for earlier intervention.